

**K173792 EliA PR3s Immunoassay**Mar 13, 2018  
89 days to decisionK173792 · Product code: **MOB** · Immunology  
Source: <https://www.510kdatabase.net/k173792/>**SUBMISSION DETAILS**

---

|                       |   |
|-----------------------|---|
| Decision              | Substantially Equivalent (Cleared)                              |
| Submission type       | Traditional   |
| Device classification | Test System, Antineutrophil Cytoplasmic Antibodies (anca) (MOB) |
| Date received         | Dec 14, 2017  |
| Decision date         | Mar 13, 2018  |
| Days to decision      | 89 days   |
| Third-party review    | No  |
| Summary / Statement   | Summary   |
| Other names           | EliA MPOs Immunoassay; EliA GBM Immunoassay                     |

**APPLICANT**

---

|                |   |
|----------------|---|
| Company        | <b>Phadia AB</b>  |
| Location       | Uppsala, SE   |
| Contact        | Carina Magnusson  |
| Website        | <a href="http://www.phadia.com">http://www.phadia.com</a> |
| 510(k) history | 32 submissions · 32 cleared · 2007-2022                   |

Phadia AB is a medical products company headquartered in Uppsala, Sweden. The company develops, manufactures, and markets blood test systems for clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases. Phadia AB received FDA 510(k) clearances from total submissions, with no denied submissions on record. The company's regulatory focus is entirely on Immunology devices. Clearances span from 2007 to 2022, establishing a consistent track record in immunoassay and allergen testing technologies. The company's cleared devices include immunoassay systems for...